Realistic expectations - The management of severe Alzheimer disease

被引:34
作者
Bullock, R [1 ]
Hammond, G [1 ]
机构
[1] Victoria Hosp, Kingshill Res Ctr, Swindon SN4 9PU, Wilts, England
关键词
pharmacologic management; severe dementia; cognitive function; disease progression; acetyleholinesterase inhibitors;
D O I
10.1097/00002093-200307003-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by a loss of memory and cognition, a decline in ability to perform activities of daily living, changes in personality and behavior, and an increase in resource utilization and medical care. The natural course of AD can be viewed as a gradual loss of independence divided into several stages (mild, moderate, and severe) that ultimately leaves the patient under the supervision of a caregiver. Acetylcholinesterase inhibitors are the most widely accepted and proven approach to the treatment of mild to moderate AD. However, management of patients with severe AD poses challenges to physicians because there are only limited treatment options for these patients. This article provides overviews of the natural history, current therapy, and diagnostic scales of AD, focusing on management of patients with severe AD. In addition, a brief summary of the existing clinical trials conducted in severe AD is presented.
引用
收藏
页码:S80 / S85
页数:6
相关论文
共 35 条
[1]  
[Anonymous], 1998, Int J Geriatr Psychopharmacol
[2]   Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications [J].
Baladi, JF ;
Bailey, PAB ;
Black, S ;
Bouchard, RM ;
Farcnik, KD ;
Gauthier, S ;
Kertesz, A ;
Mohr, E ;
Robillard, A .
CLINICAL THERAPEUTICS, 2000, 22 (12) :1549-1561
[3]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[4]  
BOSANQUET N, 1998, ALZHEIMERS DIS UNITE
[5]   The effects of donepezil in Alzheimer's disease -: Results from a multinational trial [J].
Burns, A ;
Rossor, M ;
Hecker, J ;
Gauthier, S ;
Petit, H ;
Möller, HJ ;
Rogers, SL ;
Friedhoff, LT .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) :237-244
[6]  
CARO JJ, 2001, 7 NEUROLOGICAL ASS
[7]   Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease [J].
Doody, RS ;
Dunn, JK ;
Clark, CM ;
Farlow, M ;
Foster, NL ;
Liao, T ;
Gonzales, N ;
Lai, E ;
Massman, P .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (04) :295-300
[8]  
Doody RS, 2001, NEUROLOGY, V56, pA456
[9]   Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease [J].
Doody, RS ;
Geldmacher, DS ;
Gordon, B ;
Perdomo, CA ;
Pratt, RD .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :427-433
[10]   ESTIMATED PREVALENCE OF ALZHEIMERS-DISEASE IN THE UNITED-STATES [J].
EVANS, DA .
MILBANK QUARTERLY, 1990, 68 (02) :267-289